Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [        166Ho]-Scout Over [        99mTc]MAA in a Prospective Cohort Study

Martijn E H M Wagemans; Arthur J A T Braat; Rob van Rooij; Maarten L J Smits; Rutger C G Bruijnen; Jip F Prince; Guus M Bol; Hugo W A M de Jong; Marnix G E H Lam

doi:10.1007/s00270-023-03656-y

Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ 166Ho]-Scout Over [ 99mTc]MAA in a Prospective Cohort Study

Martijn E H M Wagemans^*
, Arthur J A T Braat
, Rob van Rooij
, Maarten L J Smits
, Rutger C G Bruijnen
, Jip F Prince
, Guus M Bol
, Hugo W A M de Jong
, Marnix G E H Lam

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Downloads (Pure)

Abstract

Purpose: Radiation pneumonitis is a serious complication of radioembolization. In holmium-166 ([¹⁶⁶Ho]) radioembolization, the lung mean dose (LMD) can be estimated (eLMD) using a scout dose with either technetium-99 m-macroaggregated albumin ([^99mTc]MAA) or [¹⁶⁶Ho]-microspheres. The accuracy of eLMD based on [^99mTc]MAA (eLMD_MAA) was compared to eLMD based on [¹⁶⁶Ho]-scout dose (eLMD_Ho-scout) in two prospective clinical studies. Materials and Methods: Patients were included if they received both scout doses ([^99mTc]MAA and [¹⁶⁶Ho]-scout), had a posttreatment [¹⁶⁶Ho]-SPECT/CT (gold standard) and were scanned on the same hybrid SPECT/CT system. The correlation between eLMD_MAA/eLMD_Ho-scout and LMD_Ho-treatment was assessed by Spearman’s rank correlation coefficient (r). Wilcoxon signed rank test was used to analyze paired data. Results: Thirty-seven patients with unresectable liver metastases were included. During follow-up, none developed symptoms of radiation pneumonitis. Median eLMD_MAA (1.53 Gy, range 0.09–21.33 Gy) was significantly higher than median LMD_Ho-treatment (0.00 Gy, range 0.00–1.20 Gy; p < 0.01). Median eLMD_Ho-scout (median 0.00 Gy, range 0.00–1.21 Gy) was not significantly different compared to LMD_Ho-treatment (p > 0.05). In all cases, eLMD_MAA was higher than LMD_Ho-treatment (p < 0.01). While a significant correlation was found between eLMD_Ho-scout and LMD_Ho-treatment (r = 0.43, p < 0.01), there was no correlation between eLMD_MAA and LMD_Ho-treatment (r = 0.02, p = 0.90). Conclusion: [¹⁶⁶Ho]-scout dose is superior in predicting LMD over [^99mTc]MAA, in [¹⁶⁶Ho]-radioembolization. Consequently, [¹⁶⁶Ho]-scout may limit unnecessary patient exclusions and avoid unnecessary therapeutic activity reductions in patients eligible for radioembolization. Trail registration: NCT01031784, registered December 2009. NCT01612325, registered June 2012. Graphical Abstract: (Figure presented.)

Original language	English
Pages (from-to)	443-450
Number of pages	8
Journal	Cardiovascular and Interventional Radiology
Volume	47
Issue number	4
Early online date	7 Feb 2024
DOIs	https://doi.org/10.1007/s00270-023-03656-y
Publication status	Published - Apr 2024

Keywords

Holmium-166
Lung mean dose
Radiation pneumonitis
Radioembolization
SPECT/CT

Access to Document

10.1007/s00270-023-03656-yLicence: CC BY

s00270-023-03656-yFinal published version, 752 KBLicence: CC BY

Cite this

Wagemans, M. E. H. M., Braat, A. J. A. T., van Rooij, R., Smits, M. L. J., Bruijnen, R. C. G., Prince, J. F., Bol, G. M., de Jong, H. W. A. M., & Lam, M. G. E. H. (2024). Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ 166Ho]-Scout Over [ 99mTc]MAA in a Prospective Cohort Study. Cardiovascular and Interventional Radiology, 47(4), 443-450. https://doi.org/10.1007/s00270-023-03656-y

@article{85172021864d445f80ef469a38a71b59,

title = "Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ 166Ho]-Scout Over [ 99mTc]MAA in a Prospective Cohort Study",

abstract = "Purpose: Radiation pneumonitis is a serious complication of radioembolization. In holmium-166 ([166Ho]) radioembolization, the lung mean dose (LMD) can be estimated (eLMD) using a scout dose with either technetium-99 m-macroaggregated albumin ([99mTc]MAA) or [166Ho]-microspheres. The accuracy of eLMD based on [99mTc]MAA (eLMDMAA) was compared to eLMD based on [166Ho]-scout dose (eLMDHo-scout) in two prospective clinical studies. Materials and Methods: Patients were included if they received both scout doses ([99mTc]MAA and [166Ho]-scout), had a posttreatment [166Ho]-SPECT/CT (gold standard) and were scanned on the same hybrid SPECT/CT system. The correlation between eLMDMAA/eLMDHo-scout and LMDHo-treatment was assessed by Spearman{\textquoteright}s rank correlation coefficient (r). Wilcoxon signed rank test was used to analyze paired data. Results: Thirty-seven patients with unresectable liver metastases were included. During follow-up, none developed symptoms of radiation pneumonitis. Median eLMDMAA (1.53 Gy, range 0.09–21.33 Gy) was significantly higher than median LMDHo-treatment (0.00 Gy, range 0.00–1.20 Gy; p < 0.01). Median eLMDHo-scout (median 0.00 Gy, range 0.00–1.21 Gy) was not significantly different compared to LMDHo-treatment (p > 0.05). In all cases, eLMDMAA was higher than LMDHo-treatment (p < 0.01). While a significant correlation was found between eLMDHo-scout and LMDHo-treatment (r = 0.43, p < 0.01), there was no correlation between eLMDMAA and LMDHo-treatment (r = 0.02, p = 0.90). Conclusion: [166Ho]-scout dose is superior in predicting LMD over [99mTc]MAA, in [166Ho]-radioembolization. Consequently, [166Ho]-scout may limit unnecessary patient exclusions and avoid unnecessary therapeutic activity reductions in patients eligible for radioembolization. Trail registration: NCT01031784, registered December 2009. NCT01612325, registered June 2012. Graphical Abstract: (Figure presented.)",

keywords = "Holmium-166, Lung mean dose, Radiation pneumonitis, Radioembolization, SPECT/CT",

author = "Wagemans, \{Martijn E H M\} and Braat, \{Arthur J A T\} and \{van Rooij\}, Rob and Smits, \{Maarten L J\} and Bruijnen, \{Rutger C G\} and Prince, \{Jip F\} and Bol, \{Guus M\} and \{de Jong\}, \{Hugo W A M\} and Lam, \{Marnix G E H\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = apr,

doi = "10.1007/s00270-023-03656-y",

language = "English",

volume = "47",

pages = "443--450",

journal = "Cardiovascular and Interventional Radiology",

issn = "0174-1551",

publisher = "Springer",

number = "4",

}

Wagemans, MEHM, Braat, AJAT, van Rooij, R, Smits, MLJ, Bruijnen, RCG, Prince, JF, Bol, GM , de Jong, HWAM & Lam, MGEH 2024, 'Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ 166Ho]-Scout Over [ 99mTc]MAA in a Prospective Cohort Study', Cardiovascular and Interventional Radiology, vol. 47, no. 4, pp. 443-450. https://doi.org/10.1007/s00270-023-03656-y

Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ 166Ho]-Scout Over [ 99mTc]MAA in a Prospective Cohort Study. / Wagemans, Martijn E H M; Braat, Arthur J A T; van Rooij, Rob et al.
In: Cardiovascular and Interventional Radiology, Vol. 47, No. 4, 04.2024, p. 443-450.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ 166Ho]-Scout Over [ 99mTc]MAA in a Prospective Cohort Study

AU - Wagemans, Martijn E H M

AU - Braat, Arthur J A T

AU - van Rooij, Rob

AU - Smits, Maarten L J

AU - Bruijnen, Rutger C G

AU - Prince, Jip F

AU - Bol, Guus M

AU - de Jong, Hugo W A M

AU - Lam, Marnix G E H

PY - 2024/4

Y1 - 2024/4

N2 - Purpose: Radiation pneumonitis is a serious complication of radioembolization. In holmium-166 ([166Ho]) radioembolization, the lung mean dose (LMD) can be estimated (eLMD) using a scout dose with either technetium-99 m-macroaggregated albumin ([99mTc]MAA) or [166Ho]-microspheres. The accuracy of eLMD based on [99mTc]MAA (eLMDMAA) was compared to eLMD based on [166Ho]-scout dose (eLMDHo-scout) in two prospective clinical studies. Materials and Methods: Patients were included if they received both scout doses ([99mTc]MAA and [166Ho]-scout), had a posttreatment [166Ho]-SPECT/CT (gold standard) and were scanned on the same hybrid SPECT/CT system. The correlation between eLMDMAA/eLMDHo-scout and LMDHo-treatment was assessed by Spearman’s rank correlation coefficient (r). Wilcoxon signed rank test was used to analyze paired data. Results: Thirty-seven patients with unresectable liver metastases were included. During follow-up, none developed symptoms of radiation pneumonitis. Median eLMDMAA (1.53 Gy, range 0.09–21.33 Gy) was significantly higher than median LMDHo-treatment (0.00 Gy, range 0.00–1.20 Gy; p < 0.01). Median eLMDHo-scout (median 0.00 Gy, range 0.00–1.21 Gy) was not significantly different compared to LMDHo-treatment (p > 0.05). In all cases, eLMDMAA was higher than LMDHo-treatment (p < 0.01). While a significant correlation was found between eLMDHo-scout and LMDHo-treatment (r = 0.43, p < 0.01), there was no correlation between eLMDMAA and LMDHo-treatment (r = 0.02, p = 0.90). Conclusion: [166Ho]-scout dose is superior in predicting LMD over [99mTc]MAA, in [166Ho]-radioembolization. Consequently, [166Ho]-scout may limit unnecessary patient exclusions and avoid unnecessary therapeutic activity reductions in patients eligible for radioembolization. Trail registration: NCT01031784, registered December 2009. NCT01612325, registered June 2012. Graphical Abstract: (Figure presented.)

AB - Purpose: Radiation pneumonitis is a serious complication of radioembolization. In holmium-166 ([166Ho]) radioembolization, the lung mean dose (LMD) can be estimated (eLMD) using a scout dose with either technetium-99 m-macroaggregated albumin ([99mTc]MAA) or [166Ho]-microspheres. The accuracy of eLMD based on [99mTc]MAA (eLMDMAA) was compared to eLMD based on [166Ho]-scout dose (eLMDHo-scout) in two prospective clinical studies. Materials and Methods: Patients were included if they received both scout doses ([99mTc]MAA and [166Ho]-scout), had a posttreatment [166Ho]-SPECT/CT (gold standard) and were scanned on the same hybrid SPECT/CT system. The correlation between eLMDMAA/eLMDHo-scout and LMDHo-treatment was assessed by Spearman’s rank correlation coefficient (r). Wilcoxon signed rank test was used to analyze paired data. Results: Thirty-seven patients with unresectable liver metastases were included. During follow-up, none developed symptoms of radiation pneumonitis. Median eLMDMAA (1.53 Gy, range 0.09–21.33 Gy) was significantly higher than median LMDHo-treatment (0.00 Gy, range 0.00–1.20 Gy; p < 0.01). Median eLMDHo-scout (median 0.00 Gy, range 0.00–1.21 Gy) was not significantly different compared to LMDHo-treatment (p > 0.05). In all cases, eLMDMAA was higher than LMDHo-treatment (p < 0.01). While a significant correlation was found between eLMDHo-scout and LMDHo-treatment (r = 0.43, p < 0.01), there was no correlation between eLMDMAA and LMDHo-treatment (r = 0.02, p = 0.90). Conclusion: [166Ho]-scout dose is superior in predicting LMD over [99mTc]MAA, in [166Ho]-radioembolization. Consequently, [166Ho]-scout may limit unnecessary patient exclusions and avoid unnecessary therapeutic activity reductions in patients eligible for radioembolization. Trail registration: NCT01031784, registered December 2009. NCT01612325, registered June 2012. Graphical Abstract: (Figure presented.)

KW - Holmium-166

KW - Lung mean dose

KW - Radiation pneumonitis

KW - Radioembolization

KW - SPECT/CT

UR - https://www.scopus.com/pages/publications/85184429590

U2 - 10.1007/s00270-023-03656-y

DO - 10.1007/s00270-023-03656-y

M3 - Article

C2 - 38326577

SN - 0174-1551

VL - 47

SP - 443

EP - 450

JO - Cardiovascular and Interventional Radiology

JF - Cardiovascular and Interventional Radiology

IS - 4

ER -

Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ 166Ho]-Scout Over [ 99mTc]MAA in a Prospective Cohort Study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this